Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asia Spotlight: Ranbaxy CEO Arun Sawhney On “Thrilling” Days Of Atorvastatin Approvals And What’s Next

Executive Summary

Atorvastatin launch “reinforced the belief in the Indian generic companies,” Sawhney says. Approval of anti-malarial Synriam, the first novel drug developed in India, will lead to “belief that we from India can also develop new products.”


Related Content

Lipitor Goes Generic, But First-Filer Ranbaxy’s Approval Leaves Plenty Of Questions In Its Wake
Daiichi Sankyo Rolls Out Generics In Japan While Ranbaxy Products Still On Hold In U.S.
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
Ranbaxy Woes Continue With 30-plus Product Import Alert


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts